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Abstract
Introduction: The incidence of anaphylactic reactions during anesthesia is between 1:5000 and
1:25000 and it is one of the few causes of mortality directly related to general anesthesia. The most
important requirements in the treatment of this clinical condition are early diagnosis and
maintenance of vital organ perfusion. Epinephrine administration is generally considered as the first
line treatment of anaphylactic reactions. However, recently, new pharmacological approaches have
been described in the treatment of different forms of vasoplegic shock.
Case presentation: We describe the case of a child who was undergoing surgery for ventricular
septal defect, with an anaphylactic reaction to heparin that was refractory to epinephrine infusion
and was effectively treated by low dose vasopressin infusion.
Conclusion: In case of anaphylactic shock, continuous infusion of low-dose vasopressin might be
considered after inadequate response to epinephrine, fluid resuscitation and corticosteroid
administration.
Introduction
The incidence of anaphylactic reactions during anesthesia
is between 1:5000 and 1:25000 and it is one of the few
causes of mortality directly related to general anesthesia
[1]. The most important requirements in the treatment of
this clinical condition are early diagnosis and mainte-
nance of vital organ perfusion. Epinephrine administra-
tion is generally considered as the first line treatment of
anaphylactic reactions [1]. However, recently, new phar-
macological approaches have been described in the treat-
ment of different forms of vasoplegic shock [2]. We
describe a case in which low dose vasopressin promply re-
established hemodynamic stability in a vasoplegic state
due to an anaphylactic reaction that was refractory to
epinephrine infusion.
Case presentation
A 6-year-old 18 kg male with a ventricular septal defect
and history of asthma was scheduled for surgical correc-
tion. The patient had never undergone general anesthesia
and had a past medical history of bronchial asthma
treated with inhaled salbutamol. General anesthesia was
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induced with 0.2 mg/kg of midazolam, 0.2 mg/kg cisatra-
curium besylate and 0.5 mcg/kg remifentanil. Intravenous
general anesthesia was maintained with continuous infu-
sion of remifentanil (0.25–0.5 mcg/kg/min), cisatracu-
rium besylate (0.2 mg/kg/hr) and midazolam (0.2 mg/kg/
hr). Continuous monitoring included electrocardiogram,
invasive systemic arterial pressure (SAP) and central
venous pressure (CVP), transcutaneous arterial oxygen
saturation (SatO2), end tidal CO2 (Et CO2), cerebral satu-
ration detected by near infrared spectroscopy monitoring
(cSvO2), and peripheral, rectal and nasopharyngeal tem-
perature. After induction vital signs were stable: SAP 80/
40 mmHg, heart rate (HR) 110 beats/min, SatO2 98%,
CVP 8 mmHg, EtCO2 34 mmHg, cSvO2 80%.
Antibiotic therapy (amoxicillin/clavulanate potassium)
and methylprednisolone (30 mg/kg) were administered
as routine before sternotomy incision. Before starting car-
diopulmonary bypass (CPB), 380 UI/kg of heparin were
given and after about 60 seconds a sudden cutaneous rush
and hemodynamic instability with severe hypotension
appeared: SAP decreased to 40/25 mmHg, HR raised to
180 bpm, CVP fell to 1 mmHg, cSvO2 fell below 40%. Air-
way pressure increased to 5.06 kPa with the clinical find-
ing of bilateral pulmonary wheezing. In order to re-
establish hemodynamic stability, volume resuscitation
was started (30 ml/Kg) and two intravenous (iv) boluses
of 500 mcg of epinephrine (by institutional protocol: 25
mcg/kg every 5 minutes) were given while oxygen inspir-
atory fraction was increased to 1. CPB was instituted in 5
minutes in order to improve patient organ perfusion: CPB
pump flow initially set to 150 ml/kg/min (corresponding
to a cardiac index of 3.3 L/min/m2) generating a perfusion
pressure of 20 mmHg with systemic vascular resistances
index (SVRI) of 470 dyne*s/cm5/m2. Anaphylactic reac-
tion to heparin with a distributive shock was strongly sus-
pected. The finding of metabolic acidosis (pH 7.23) with
increased lactate levels (9 mmol/L) suggested poor tissue
perfusion due to severe hypotension-low perfusion pres-
sure with inadequate oxygen delivery to peripheral tis-
sues. Initial management of shock consisted of
moderately hypothermic (30°C) high-flow CPB (220 ml/
kg/min) with hematocrit increased from 30% to 35% by
transfusion of 200 ml of packed red blood cell. Moreover,
epinephrine infusion was started at a dose to 0.1 mcg/kg/
min in order to achieve a perfusion pressure of 40 mmHg.
Metabolic acidosis progressively improved (pH = 7.38)
with an initial reduction in plasma lactate levels (5.1
mmol/L). When vital parameters seemed adequately sta-
ble, the surgical procedure was performed with a CPB
time of 25 minutes. During this time, the epinephrine
infusion could not be stopped and the first weaning from
CPB failed because of severe hypotension (mean SAP = 30
mmHg) despite epinephrine administration being titrated
up to 0.3 mcg/kg/min. Arginine-vasopressin (Pitressin;
Monarch Pharmaceuticals, Bristol, United Kingdom)
infusion was started at a rate of 0.0003 U.I./Kg/min.
Within 5 minutes, a pump flow at 100 ml/kg/min gener-
ated a perfusion pressure of 40 mmHg with a significant
rise of SVRI to 1400 dyne*s/cm5/m2.
Epinephrine infusion was immediately reduced to 0.05
mcg/kg/min and the patient was successfully weaned
from CPB with stable hemodynamic parameters. Pro-
tamine was administered without any adverse effect. After
admission to the pediatric cardiac intensive care (PCICU),
the patient's hemodynamics were stable and urine output
was 3 ml/kg/h without any electrolytic disorder. Lactate
levels returned to normal values within 6 hours. Vaso-
pressin was progressively reduced by 0.0001 U.I./Kg/min
every 2 hours, controlling SAP to more than 80/40
mmHg, and stopped after 6 hours infusion. Epinephrine
was reduced and stopped in 12 hours with the same
hemodynamic goal. The patient was extubated 12 hours
after the surgical procedure and discharged from PCICU
after 24 hours. No adverse effects due to the vasopressin
administration were reported.
Discussion
Anaphylactic and anaphylactoid reactions during anesthe-
sia are generally caused by neuromuscular blocking
agents, some general anesthetics, antibiotics, blood prod-
ucts, opioids, latex and rarely by anticoagulant agents
such as heparins [3]. Cardiovascular collapse due to ana-
phylaxis is a vasodilatory shock, characterized by an
abrupt fall in systemic vascular resistance, enhanced vas-
cular permeability, intravascular volume depletion and
metabolic acidosis with hyperlactatemia.
Metabolic acidosis is mainly derived from poor tissue per-
fusion due to severe hypotension and low perfusion pres-
sure rather than inadequate systemic oxygen delivery
only. The distribution of cardiac output to the various
organs and to the regulation of the microcirculation that
can be substantially altered in several conditions (i.e. dis-
tributive shock) where local control of vascular tone is
altered and the formation of edema may contribute to
damage to the distribution of blood flow. Multiple medi-
ators from mast cells, such as kinins, leukotrienes and
prostanoids, are implicated in promoting vasodilatation,
but histamine seems to play the major role [4]. Stimula-
tion of histamine-H1 receptors on endothelium cells acti-
vates both the nitric oxide (NO) and the prostacycline
mediated vasodilating pathways [5]. Activation of induci-
ble NO synthase (iNOS) is a major contributor to both
vasodilatation and resistance to the catecholamine vaso-
pressor effect. NO decreases myosin light chain phospho-
rylation and activates calcium-sensitive (KCa) and
adenosine triphosphate-sensitive (KATP) potassium chan-Journal of Medical Case Reports 2008, 2:36 http://www.jmedicalcasereports.com/content/2/1/36
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nels in the plasma membrane of vascular smooth-muscle
cells through both direct and cyclic guanosine monophos-
phate (cGMP) pathways [4]. Potassium channel activa-
tion results in K efflux, cellular hyperpolarization, closure
of the voltage-gate calcium channels and blunting of the
intracytosolic calcium rise sustaining vasoconstriction.
Finally, prolonged low systemic hypoperfusion with tis-
sue hypoxia and lactic acidosis can maintain all the
described pathophysiologic mechanisms and induce a rel-
ative deficiency in vasopressin plasma concentration fur-
ther amplifying the vasoplegic scenario [5]. Despite the
presence of histamine receptors the heart is not the target
organ and cardiac abnormalities during anaphylactic reac-
tion are due to severe impairment in perfusion pressure or
to side effects of administered catecholamines [6]. Epine-
phrine has been widely accepted to be the standard med-
ical therapy to reverse cardiovascular collapse in
anaphylaxis. Because of its α and β adrenergic effects,
epinephrine inhibits further vasodilating mediator release
from basophils and mast cells, reduces bronchonstriction,
increases vascular tone and improves cardiac output. Nev-
ertheless, in the complex pathophysiologic mechanism of
anaphylactic shock, inotropic resistance has been
described and epinephrine may fail to reverse vasodila-
tion [7,8] while sustaining undesidered effects related to
increased myocardial oxygen consumption. Recently, the
successful use of vasopressin to treat septic and postcardi-
otomy shock has been documented [2,9] and pathophys-
iologic considerations supporting its role in the treatment
of vasodilatory shock have been demonstrated. Vaso-
pressin inhibits the synthesis of iNOS, blunts the increase
in cGMP induced by NO and directly inactivates KATP
channels in vascular smooth muscle [10]. Moreover, vaso-
pressin is able to enhance endogenous catecholamine-
induced vasoconstriction [11]. Despite the evidence that
anaphylaxis causes a clinical picture of intense vasodila-
tion, there are few cases reporting vasopressin administra-
tion to treat anaphylactic shock [12]. To our knowledge
this is the first case report documenting the evidence of
efficacy of vasopressin administration in anaphylactic
shock in pediatric cardiac surgery. Our patient did not
respond adequately to volume expansion and epine-
phrine infusions. Our decision to start CPB might have
been questionable since the patient might have been sta-
bilized with epinephrine and vasopressin and the case
rescheduled.
Nevertheless, our choice was made in order to urgently
restore adequate ventilatory parameters and to improve
organ perfusion within the extracorporeal circuit before
the clinical picture of severe vasoplegic shock was com-
pletely defined. It must be considered that CPB might also
have initially worsened the clinical picture since, once the
inflammatory system is activated, it is likely that CPB will
add further activation. However, only the administration
of low dose vasopressin was effective in restoring ade-
quate systemic vascular resistance and allowed for a suc-
cessful CPB weaning and stable postoperative
hemodynamic parameters. Given the the existing contro-
versy on which agent should be preferably used in case of
vasoplegic shock [13], our decision to use vasopressin was
related to other recent available experiences [12], the
above described pharmacological rationale and the choice
of avoiding escalating therapy with alpha agonists. This
pharmacological approach allowed us to titrate the drug
to the minimum required dose and avoided side effects
reported with high vasopressin doses such as reduction of
diuretic output and hyponatremia [14]. The adequacy of
tissue peripheral perfusion was confirmed by the postop-
erative normalization of plasma lactate levels.
Conclusion
In case of anaphylactic shock, continuous infusion of low-
dose vasopressin might be considered in the treatment
algorithm after inadequate response to epinephrine, fluid
resuscitation and corticosteroid administration. Vaso-
pressin may help to promptly and effectively restore
hemodynamic stability and adequate systemic oxygen
delivery before the disastrous effects of massive distribu-
tive shock can lead to severe organ hypoperfusion and cell
death.
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